The pertuzumab clinical dosing regimen of a 840 mg fixed loading dose followed by 420 mg every three weeks was selected based on PK and safety data from studies where pertuzumab was administered as a single agent to patients with advanced refractory solid tumors, including ovarian cancer, metastatic breast cancer (low HER2 expressing), and hormone-refractory prostate cancer. The gene discussed is ERBB2; the disease is ovarian cancer.